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Suberoylanilide hydroxamic acid (SAHA), an orally administered inhibitor of histone deacetylases, is currently in
phase II clinical trials for cutaneous T cell lymphomas (CTCL), but the mechanism of SAHA action is unknown. In
this study, we investigated the anti-tumor effects of SAHA in CTCL cell lines and freshly isolated peripheral blood
lymphocytes (PBL) from CTCL patients with high percentage of circulating malignant T cells. Three cell lines (MJ,
Hut78, and HH) and PBL from 11 patients and three healthy donors were treated with SAHA (1, 2.5, and 5 lM) for 24
and/or 48 h. Apoptosis was determined by ﬂow cytometry analysis of sub-G1 hypodiploid nuclei and/or annexin V
binding populations. Acetylated histones and apoptosis-associated proteins were detected by Western blotting.
SAHA at 1–5 lM for 24 and 48 h induced apoptosis in a concentration- and time-dependent manner in three cell
lines: MJ (0%–7% and 1%–32%), Hut78 (4%–36% and 5%–54%), and HH (4%–67% and 8%–81%). SAHA at 1–5 lM for
48 h also induced more apoptosis of patients’ PBL than healthy donors’ (15%–32% versus 6%–13%, po0.05). SAHA
treatment caused an accumulation of acetylated histones (H2B, H3, and H4), an increase of p21WAF1 and bax
proteins, a decrease of Stat6 and phospho-Stat6 proteins, and activation of caspase-3 in CTCL cells. Our data
suggest that selective induction of malignant T cell apoptosis and modulation of acetylated histones, p21WAF1, bax,
Stat6, and caspase-3 may underlie the therapeutic action of SAHA in CTCL patients.
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Cutaneous T cell lymphomas (CTCL) are extranodal non-
Hodgkin’s lymphomas with pleomorphic skin lesions and
distinct T-cell markers. Mycosis fungoides (MF), the most
common and indolent form of CTCL, is characterized by
malignant CD4þCD45ROþCLAþCCRþ T cells that also
lack CD7 and/or CD26. MF may evolve into a leukemic
variant, Se´zary syndrome (SS), or transform to large cell
lymphoma. As MF/SS advances, the clonal dominance of
the malignant cells results in the expression of predomi-
nantly Th2 cytokines, progressive immune dysregulation in
patients, and further tumor cell growth (Kim et al, 2005).
Early MF can often be controlled with skin directed topical
steroids, retinoids, or chemotherapy with phototherapy,
systemic biological response modifiers, or total skin elec-
tron beam irradiation. Although partial and complete remis-
sions can be achieved, subsequent relapses are common.
Since patients with refractory or transformed MF and SS
have a poor prognosis and therapy is palliative (Duvic and
Cather, 2000; Kim et al, 2005), new therapies are needed.
CTCL cells have defective apoptosis; therefore, reversing
resistance to apoptosis may provide a new therapeutic ap-
proach (Kacinski and Flick, 2001; Meech et al, 2001; Ni et al,
2005).
Histone deacetylase (HDAC) inhibitors are a novel class
of antineoplastic agents. By blocking deacetylation of
histones, they promote an open chromatin structure and
thereby alter the expression of genes regulating cell surviv-
al, proliferation, differentiation, and apoptosis (Rosato and
Grant, 2003; Mei et al, 2004; Drummond et al, 2005). Sub-
eroylanilide hydroxamic acid (SAHA), an inhibitor of class I
and II HDAC, induces cell growth arrest and apoptosis of a
broad spectrum of transformed cells in in vitro and in vivo
studies (de Ruijter et al, 2003; Marks et al, 2003; Mei et al,
2004; Drummond et al, 2005). SAHA is currently in phase I
and II clinical trials for the treatment of various cancers and
has shown promising anticancer activity at doses that are
well tolerated by patients (Kelly et al, 2003; Piekarz and
Bates, 2004). Clinical evaluation of SAHA in patients with
CTCL has revealed that oral SAHA produces clinically
meaningful partial responses in ten of 37 advanced, heavily
pretreated patients associated with decreased pruritus.1
Abbreviations: CDK, cyclin-dependent kinase; CTCL, cutaneous T
cell lymphomas; HAT, histone acetyltransferase; HDAC, histone
deacetylase; MF, mycosis fungoides; PARP, poly (ADP-Ribose)
polymerase; PBL, peripheral blood lymphocytes; PI, propidium io-
dide; SAHA, suberoylanilide hydroxamic acid; SS, Se´zary syn-
drome; Stat, signal transducers and activators of transcription
1Duvic M, Talpur R, Zhang CL, Goy A, Richon, V, Frankel SR:
Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for
cutaneous T-cell lymphoma (CTCL) unresponsive to conventional
therapy. J Clin Oncol:23(16S) 6571, 2005 (abstr).
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SAHA’s mechanism of action in CTCL has not yet been
demonstrated. In this study, we performed in vitro transla-
tional studies to further define the anti-tumor effects of
SAHA in well-established CTCL cell lines and freshly iso-
lated peripheral blood lymphocytes (PBL) from SS/MF pa-
tients with high percentage of circulating malignant T-cells
(Bernengo et al, 2001).
Results
SAHA inhibited cell growth of CTCL cell lines To deter-
mine whether SAHA inhibits CTCL cell growth, MJ, Hut78,
and HH cell lines were treated with or without SAHA (1, 2.5,
and 5 mM) for 24 and 48 h, and their viability was evaluated
by CellTiter 96 AQ One Solution Cell Proliferation Assay. As
the dose of SAHA increased from 1 to 5 mM over 24 and
48 h, growth inhibition of HH cells increased from 2% to
34% and from 21% to 70% in a concentration- and a time-
dependent manner compared to vehicle control (n¼3,
po0.05). Similar results were also seen in the MJ and Hut78
cell lines; however, MJ cells were less sensitive to SAHA
(Fig 1A). These results demonstrated that SAHA is an in-
hibitor of CTCL cell line growth in vitro.
SAHA selectively induced apoptosis of CTCL cell lines
and patients’ PBL To determine whether growth inhibition
of SAHA is due to cell-cycle arrest and/or to apoptosis in
CTCL cell lines, MJ, Hut78, and HH cells were treated with
or without SAHA (1, 2.5, and 5 mM) for 24 and 48 h. As the
dose of SAHA increased from 1 to 5 mM over 48 h, the
percent of HH cells with sub-G1 population increased from
11% to 88% in a concentration-dependent manner com-
pared to vehicle control. As the incubation time of SAHA at
2.5 mM increased from 24 to 48 h, the percent of HH cells
with sub-G1 population increased from 37% to 80% in a
time-dependent manner compared to vehicle control (Fig
1B). Similar results were also seen in the MJ and Hut78 cell
lines (Fig 1C). An increased percentage of cells in the sub-
G1 population was accompanied by a loss of cells in the
G1, S, and G2/M phases, suggesting cells are undergoing
apoptosis (Zhang et al, 2002).
In parallel to the cell cycle analysis, we also investigated
the effect of SAHA on annexin V binding in three CTCL cell
lines. As the SAHA concentration increased from 1 to 5 mM
for 24 h, the number of HH cells stained for annexin V in-
creased from 3% to 63% in a concentration-dependent
manner compared to vehicle control. As the incubation time
of SAHA at 2.5 mM increased from 24 to 48 h, the number of
HH cells stained for annexin V increased from 43% to 63%
in a time-dependent manner compared to vehicle control
(Fig 1D). Similar results were also seen in the MJ and Hut78
cell lines but again MJ cells were less sensitive to SAHA
(Fig 1E). These results were consistent with analysis of cell-
cycle distributions from PI staining, further confirming
that CTCL cell lines undergo apoptosis following SAHA
treatment.
To confirm these findings, we also tested the pro-apo-
ptotic effect of SAHA on freshly isolated PBL from 11 SS/
MF patients with high percentage of circulating malignant T-
cells and three healthy donors. As the SAHA concentration
increased from 1 to 5 mM for 48 h, the number of patients’
PBL stained for annexin V increased from 15% to 32%
compared to vehicle control. As the SAHA concentration
increased from 1 to 5 mM for 48 h, the number of healthy
donors’ PBL stained for annexin V increased from 6% to
13% compared to vehicle control. Thus, patients’ PBL were
more sensitive to SAHA treatment than healthy donors’ PBL
(po0.05) (Table I).
SAHA induced accumulation and modulated apoptosis-
associated proteins in CTCL cells To understand the
mechanism of SAHA-induced apoptosis, western blotting
was used to examine the effects of SAHA on the accumu-
lation of acetylated histones and expression of apoptosis-
associated proteins in three CTCL cell lines and patients’
PBL undergoing apoptosis. The acetylated histones (H2B,
H3, and H4) were absent or weakly expressed in three
CTCL cell lines and patients’ PBL, and increased following
SAHA treatment (Fig 2A). The cyclin-dependent kinase
(CDK) inhibitor p21WAF1 was absent in Hut78, HH, and two
patients’ PBL but expressed in MJ, and induced following
SAHA treatment. The tumor suppressor p53 protein was
expressed in MJ, HH, and patients’ PBL but not in Hut78
cells, and did not change following SAHA treatment. Stat3
and Stat6 proteins were expressed and Stat6 but not Stat3
decreased following SAHA treatment. Stat3 and Stat6 pro-
teins were phosphorylated and phospho-Stat6 but not
Stat3 decreased following SAHA treatment. SAHA did not
change the level of anti-apoptotic protein bcl-2 but in-
creased pro-apoptotic protein bax. Caspase-3 activation
and poly (ADP-Ribose) polymerase (PARP) cleavage follow-
ing SAHA treatment were evident as shown by the appear-
ance of cleaved 20- and 17-, and 85-kDa fragments,
respectively (Fig 2B).
Discussion
In CTCL, most effective treatments including phototherapy
(Baron and Stevens, 2003), photopheresis (Zic, 2003) and
rexinoids (Zhang et al, 2002) induce apoptosis of T cells. In
this study, we show that SAHA at 1–5 mM selectively causes
apoptosis of CTCL cell lines and SS/MF patients’ PBL
compared to healthy donors’ PBL. SAHA also induced
an accumulation of acetylated histones, an increase of
p21WAF1and bax, a decrease of Stat6 and phospho-Stat6,
and activation of caspase3. Our study agrees with the find-
ing that depsipeptide (FK228), another structural class of
HDAC inhibitors, also induces apoptosis of Hut78 CTCL
cells in vitro (Piekarz et al, 2004).
An important attribute of HDAC inhibitors including SAHA
is that they induce tumor cell apoptosis at concentrations to
which normal cells are relatively resistant, making them well
suited for cancer therapy (Marks and Jiang, 2005). This dif-
ference in sensitivity to SAHA-induced apoptosis appears
not to be caused by a difference in the ability to inhibit
HDAC activity because accumulation of acetylated histones
occurs in both tumor and normal cells (Ungerstedt et al,
2005). In this study, we also showed that SAHA at 1–5 mM
selectively causes apoptosis of CTCL cell lines and pa-
tients’ PBL compared to healthy donors’ PBL. More recent
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studies showed that thioredoxin, a hydrogen donor for
many protein targets and a scavenger of ROS, is an impor-
tant determinant of resistance of cells to SAHA-induced
apoptosis (Ungerstedt et al, 2005). In our study, there is also
different sensitivity to SAHA in three cell lines and patients’
PBL. Further exploration may be needed to understand the
mechanism of sensitivity difference to SAHA in inducing
apoptosis of different CTCL cell lines and patients’ PBL.
Chromatin, the basic structural unit of DNA, is composed
of nucleosomes with approximately 146 bp of DNA
wrapped around an octamer of core histones (two mole-
cules of H2A, H2B, H3, and H4) (Mei et al, 2004; Drummond
et al, 2005). Histone acetylation plays an important role in
transcriptional regulation. The status of histone acetylation
is a dynamic process depending on a balance between the
activities of HDAC and histone acetyltransferases (HAT)
(Mei et al, 2004; Drummond et al, 2005). HAT acetylate hi-
stone lysine substrates, opening up compacted chromatin
and promoting binding of transcription factors and gene
transcription. In contrast, HDAC decrease acetylation of
histone lysine tails, thereby condensing chromatin structure
and repressing gene transcription (Mei et al, 2004; Drum-
Figure 1
Effects of suberoylanilide hydroxamic acid (SAHA) on cell growth, cell cycle, and apoptosis in cutaneous T cell lymphomas (CTCL) cell
lines. MJ, Hut78, and HH cell lines were treated with or without SAHA (1, 2.5, and 5 mM) for 24 and 48 h. (1). Inhibition of cell growth. (A) Cells were
aliquoted into a 96-well culture plate and cell viability was determined by comparing untreated control to treated groups with MTS assay performed
in triplicate. Each point represented mean  SD of triplicate determinations. (2). Increase of sub-G1 arrest. Cell-cycle distributions were determined
by DNA content analysis with propidium iodide (PI) staining and flow cytometry. (B) Induction of sub-G1 population of HH cell line in a concentration-
and time-dependent manner. (C) Each point represented the percent of cell-cycle distributions with different DNA content. Results were repre-
sentative of one of three independent experiments. (3). Induction of annexin V binding. Annexin V binding was carried out with the Annexin V-FITC
Detection Kit. (D) Induction of annexin V binding of HH cell line in a concentration- and time-dependent manner. (E) Each point represented the
percentage of both annexin VþPI and annexin VþPIþ cells (mean  SD of triplicate determinations). Significantly different from vehicle control
values (n¼ 3; po0.05).
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mond et al, 2005). Abnormal expression, function or re-
cruitment of HDAC and/or HAT is associated with neoplasia,
including lymphoid and myeloid leukemia (Vighushin and
Coombes, 2004). In this study we show that SAHA treat-
ment at concentrations causing apoptosis also induces an
accumulation of acetylated histones, which may represent a
therapeutic marker of drug activity in CTCL patients.
Despite wide distribution of HDAC in chromatin, HDAC
inhibitors including SAHA alter the expression of only a
small number of genes (2%–17%) by differential display and
DNA microarray analysis of gene profiling (Lindemann et al,
2004). Among these genes, the cdk inhibitor p21WAF1 is one
of the most commonly induced in several types of trans-
formed cells by SAHA treatment (Richon et al, 2000; Gui
et al, 2004). The upregulation of p21WAF1 is responsible for
not only cell cycle arrest but also apoptosis induced by
HDAC inhibitors (Mei et al, 2004; Somech et al, 2004). In this
study, we show that SAHA treatment at concentrations
causing apoptosis induced the expression of p21WAF1 pro-
tein without cell cycle arrest in all three CTCL cell lines,
suggesting that p21WAF1 is involved in SAHA-induced
apoptosis of CTCL cells. Furthermore, p21WAF1 is a down-
stream target of the tumor suppressor p53 and can be reg-
ulated in a p53-dependent or -independent manner (Gartel
Figure 1 Continued
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and Tyner, 1999). To address whether up-regulation of
p21WAF1 protein is related to p53, we analyzed CTCL cells
for protein expression of p53 following SAHA treatment. Our
immunoblot results showed that there was no change of
p53. Thus, up-regulation of p21WAF1 by SAHA is likely to be
independent of a wild-type p53 status (Vrana et al, 1999;
Huang et al, 2000).
HDAC have also been found in association with signal
transducers and activators of transcription (Stat) (Rascle
et al, 2003). Stat proteins comprise a family of transcription
factors latent in the cytoplasm that consists of seven dif-
ferent members: Stat1, 2, 3, 4, 5A, 5B, and 6. After activated
by phosphorylation in response to a series of cytokines,
growth factors, and hormones, Stat dimerize and translo-
cate to the nucleus where Stat bind to specific DNA pro-
moter sequences and thereby regulate gene expression
(Calo et al, 2003). Stat3 is activated by a wide variety of
extracellular and intracellular stimuli such as IL-2, IL-6, IL-7,
IL-9, IL-10, and IL-15, and by intracellular tyrosine kinases
such as src and abl (Calo et al, 2003). Constitutive activation
of Stat3 has been demonstrated to contribute to oncogen-
esis by stimulating cell proliferation and preventing apop-
tosis in a large number of solid tumors and hematological
malignancies including CTCL (Sommer et al, 2004; Turkson,
2004; Mitchell and John, 2005). In contrast, Stat6 is only
primarily activated by IL-4 and IL-13 for the development of
Th2 cells (Calo et al, 2003). The activation of Stat6 in ma-
lignancies is little known. Constitutive activation of Stat6
has been demonstrated in adult T-cell leukemia/lymphoma
(Takemoto et al, 1997), leukemia associated with the
p190bcrabl (Ilaria and Van Etten, 1996), and Hodgkin’s
lymphoma (Skinnider et al, 2002). In addition, human lymph-
ocytes with Stat6 null phenotype exhibit increased apopto-
sis (Galka et al, 2004). In this study, we found for the first
time that SAHA at concentrations causing apoptosis de-
creases the expression of Stat6 and phospho-Stat6 but not
Stat3 and phospho-Stat3 in three cell lines and patients’
PBL. Thus, down-regulation of Stat6 and phospho-Stat6
may be involved in SAHA-induced apoptosis of CTCL cells.
The balance between expression of anti-apoptotic pro-
tein bcl-2 and pro-apoptotic protein bax is critical in con-
trolling the activation of caspases by regulating release of
cytochrome c from mitochondria (Manion and Hockenbery,
2003). Bcl-2 expressed in CTCL cells, may increase survival
and resistance of CTCL cells against radiotherapy and ex-
tracorporeal photochemotherapy (Osella-Aate et al, 2001;
Breuckmann et al, 2002; Zhang et al, 2003). Among the 16
known members of interleukin-1-converting enzyme family
of proteases, caspase-3 has been shown to be a key com-
ponent of the apoptotic machinery (Porter and Ja¨nicke,
1999). Caspase-3 is activated in apoptotic cells and cleaves
several cellular proteins, including PARP. The cleavage of
PARP is a hallmark of apoptosis by various antitumor
agents (Duriez and Shah, 1997). We have previously report-
ed that caspase-3 is activated and PARP is cleaved in apo-
ptotic CTCL cells induced by bexarotene (Zhang et al, 2002)
Table I. SAHA selectively induced apoptosis of SS/MF patients’ PBL
Patient no. Age/gender Diagnosis CD4þCD26 (%)
Apoptosis (%) (48 h)a
Concentrations (lM)
1 2.5 5
1 75/F SS 95 19 34 45
2 69/F SS 82 35 58 59
3 61/F SS 83 8 18 18
4 44/F MF 40 3 3 5
5 76/F SS 91 11 24 24
6 75/M SS 84 24 45 53
7 58/M SS 67 35 55 56
8 81/F MF 37 12 23 20
9 67/M SS 61 4 21 29
10 59/F SS 79 9 19 24
11 54/M SS 97 6 16 18
Statistic analysis
Total (mean  SD)
Patients (n¼ 11) 15  11 29  17 32  18
Healthy donors (n¼3) 6  2 11  3 13  5
p value Patients versus healthy donors p¼0.03 p¼ 0.006 p¼0.009
aApoptosis was determined by flow cytometry analysis of annexin V/PI staining. The values represented the percentage of annexin VþPI and
annexin VþPIþ binding from PBL treated with different concentrations of SAHA over vehicle control.
SAHA, suberoylanilide hydroxamic acid; SS, Se´zary syndrome; MF, mycosis fungoides; PBL, peripheral blood lymphocytes; M, male; F, female.
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and CDDO (Zhang et al, 2004). In this study, we show that
SAHA at concentrations causing apoptosis did not change
bcl-2 but increased bax, activated caspase-3, and cleaved
PARP in three CTCL lines and patients’ PBL. Thus, altera-
tion of bax/bcl-2 ratio, activation of caspase-3, and cleav-
age of PARP are likely involved in SAHA-induced apoptosis
of CTCL cells.
In conclusion, we have demonstrated that SAHA selec-
tively induces apoptosis of CTCL cell lines and freshly iso-
lated PBL from SS/MF patients with high percentage of
circulating malignant T-cells. These events are associated
with an accumulation of acetylated histones, an increase of
p21WAF1, an alteration of bax/bcl-2 ratio, a decrease of
Stat6 and phospho-Stat6 proteins, an activation of ca-
spase-3, and a cleavage of PARP. These findings support
the therapeutic action of SAHA in ongoing phase I and II
clinical trials for CTCL patients. Further exploration may be
needed to identify more targeted genes of SAHA that could
be used as surrogate end points to analyze SAHA and other
HDAC inhibitors in clinical development.
Materials and Methods
Reagents SAHA was provided by Merck (Boston, Massachu-
setts). SAHA was dissolved in DMSO to stock concentration of
10 mM and stored at 201C. Serial dilutions (1, 2.5, and 5 mM)
were freshly made in RPMI 1640.
Cells and cell culture Human CTCL cell lines MJ (G11), Hut78,
and HH obtained from American Type Culture Collection (Rockville,
Maryland) were derived from peripheral blood of patients with MF,
SS, and non-MF/SS aggressive CTCL, respectively (Gootenberg
et al, 1981; Popovic et al, 1983; Starkebaum et al, 1991). Samples
of peripheral blood were obtained for in vitro studies from three
healthy donors and eleven SS/MF patients with high percentage of
Figure2
Effects of suberoylanilide hydro-
xamic acid (SAHA) on modula-
tion of acetylated histones (A)
and apoptosis-associated pro-
teins (B) in cutaneous T cell
lymphomas (CTCL) cell lines
and patients’ peripheral blood
lympocytes (PBL). Cellular pro-
teins from three cell lines (MJ,
Hut78, and HH) and PBL from
two patients with Se´zary syndrome
treated with SAHA at 2.5 mM (5
mM for MJ) for 24 h were fraction-
ated by 8%–12% SDS-PAGE,
transferred onto nitrocellulose
membranes and subjected to ECL
detection analysis. The equivalent
loading of proteins in each well
was confirmed by actin. Results
were representative of one of two
independent experiments.
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circulating malignant Tcells (Table I). Samples were obtained during
routine diagnostic assessments after informed consent was ob-
tained in accordance with regulations and protocols sanctioned by
the Human Subjects Committee of M. D. Anderson. The study was
conducted according to the Declaration of Helsinki Principles. PBL
from these patients and healthy donors were isolated by Vacutainer
CPT (Becton Dicknson, San Jose, California). Cells were grown in
RPMI 1640 medium (Sigma Chemical, St. Louis, Missouri) supple-
mented with 10% heat-inactivated fetal bovine serum (HyClone
Laboratories, Logan, Utah), 2 mM HEPES, and 1% penicillin–
streptomycin in a humidified atmosphere with 5% CO2 at 371C.
Cell viability Cell viability was measured by CellTiter 96 AQ One
Solution Cell Proliferation Assay (Goodwin et al, 1995) according to
the manufacturer’s instructions (Promega, Madison, Wisconsin).
Aliquots of 5  104 cells per well were distributed in 96-well micro-
plates (Falcon; New Jersey) in 100 mL of medium and incubated
with SAHA (1, 2.5, and 5 mM) for 24 and 48 h, then 20 mL of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt was added to each well and incubated
for an additional 4 h. The relative cell viability was determined at
490 nm using 96-well plate reader. Each experiment was per-
formed in triplicate, and repeated a minimum of three times.
Flow cytometry analysis of cell cycle MJ, Hut78, and HH cells
(1  106 cells) were incubated with or without SAHA (1, 2.5, 5 mM)
for 24 and 48 h. Cells were collected, washed with cold phosphate-
buffered saline (PBS), fixed in cold (201C) 100% ethanol, treated
with DNase-free RNase, and stained with 50 mg per mL propidium
iodide (PI). Distribution of the cell-cycle phase by different DNA
content was determined with a FACScan flow cytometer (Becton
Dickinson). For each sample, 10,000-gated events were acquired.
Analyses of cell-cycle distribution (including apoptosis: sub-G1)
were performed using Modfit software (Becton Dickinson).
Annexin V binding staining The analysis of annexin V binding
was carried out with an Annexin V-FITC Detection Kit I (PharMin-
gen, San Diego, California) according to the manufacturer’s in-
structions. Briefly, three cell lines and PBL from healthy donors and
patients were incubated with or without SAHA (1, 2.5, and 5 mM) for
24 and/or 48 h. Cells were collected, washed twice with cold PBS,
and centrifuged at 500  g for 5 min. Cells were resuspended in
1  binding buffer at a concentration of 1  106 cells per mL, 100
mL of the solution were transferred to a 5 mL culture tube, and 5 mL
of annexin V-FITC and 5 mL of PI were added. Cells were gently
vortexed and incubated for 15 min at room temperature in the dark.
Finally, 400 mL of 1  binding buffer was added to each tube, and
samples were analyzed by FACScan flow cytometer (Becton Dic-
kinson). For each sample, 10,000 ungated events were acquired.
Annexin VþPI cells represent the early apoptotic populations.
Annexin VþPIþ cells represent either late apoptotic or secondary
necrotic populations.
Isolation of cytoplasmic and nuclear extracts Cells (5  106)
were washed with ice-cold PBS, harvested into 1 mL of PBS, pel-
leted in a 1.5-mL microcentrifuge tube, and suspended in 400 mL of
buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, and 1  protease inhibitor cocktail ‘‘complete
mini’’ (Roche, Indianapolis, Indiana)). After a 20-min incubation on
ice, the mixture was treated with a 24-G syringe for five times and
then centrifuged briefly to obtain the cytoplasmic supernatant. The
nuclear pellet was resuspended in 40–80 mL of buffer C (10 mM
HEPES (pH 7.9), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
10% glycerol, and 1  protease inhibitor cocktail ‘‘complete mini’’
(Roche)) and incubated at 41C with shaking for 15 min. Protein
concentrations were determined by the Bradford dye-binding pro-
tein assay (Bio-Rad, Richmond, California) using bovine serum
albumin as a standard.
Western blot analysis Western blot analysis was carried out as
described previously (Zhang et al, 2002). Briefly, cytoplasmic
(10 mg) or nuclear (5 mg) proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel (8%–12%) electrophoresis (SDS-PAGE)
and transferred onto nitrocellulose membranes (Schleicher &
Schuell, Dasse, Germany). The membranes were blocked in 3%
powdered milk in TBST (50 mM Tris (pH 7.5), 150 mM NaCl, 0.05%
Tween 20), incubated with primary antibody overnight at 41C in 3%
powdered milk in TBST, and washed extensively with TBST. They
were incubated with 1:5000 peroxidase-conjugated anti-mouse or
anti-rabbit secondary antibody (Jackson ImmunoResearch, West
Grove, Pennsylvania) for 1 h at room temperature. Polyclonal rabbit
anti-acetyl-histones (H2B, H3 and H4), and anti-Stat6 and bax an-
tibodies were obtained from Upstate Biotechnology (Lake Placid,
New York) and Santa Cruz Biotechnology (Santa Cruz, California),
respectively. Monoclonal mouse anti-p21WAF1 and anti-Stat3 anti-
bodies were obtained from Oncogene (Boston, Massachusetts)
and BD Biosciences (San Diego, California), respectively. Mono-
clonal mouse anti-p53, bcl-2, pro-caspase-3, and PARP antibodies
were obtained from Santa Cruz Biotechnology. Monoclonal mouse
anti-phospho-Stat3, phospho-Stat6, and rabbit anti-caspase-3
antibodies were obtained from Cell Signaling (Beverly, Massachu-
setts). Immunoreactive bands were visualized by enhanced chemi-
luminescence detection kit (Amersham, Buckinghamshire, UK).
The equivalent loading of proteins in each well was confirmed by
actin and Ponceau staining.
Statistical analysis All experiments were performed in triplicate
unless otherwise noted. Results were expressed as means  SD.
Statistical significance was evaluated by Student’s t test, and
po0.05 was considered as significant.
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